Core Insights - MediWound's NexoBrid will be featured in 36 scientific presentations at the 21st European Burns Association Congress, emphasizing its significance in burn care advancements [1][2][3] Group 1: NexoBrid's Clinical Impact - Presentations will showcase data on pediatric, elderly, and critically burned patients, demonstrating consistent benefits in survival, recovery, and scar outcomes, as well as its effectiveness in infection control and modulation of systemic inflammatory responses [2] - Comparative and long-term studies support NexoBrid's superiority over surgical excision, reinforcing its role in routine care and mass casualty scenarios [2] Group 2: Company Overview - MediWound Ltd. is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair, with NexoBrid being its FDA-approved biologic for the enzymatic removal of eschar in thermal burns [6] - The company is also advancing EscharEx, a late-stage investigational therapy for chronic wound debridement, which has shown clinical advantages over leading products [6] Group 3: Support and Funding - NexoBrid's development has received federal funding from the U.S. Department of Health and Human Services and BARDA, supporting pivotal clinical studies and the marketing approval process [5]